Regeneron Pharmaceuticals, Inc.
Christopher R. Fenimore (EVP Finance CFO) reports REGN insider transactions
Summary from the key facts
Christopher R. Fenimore (EVP Finance CFO) at Regeneron Pharmaceuticals, Inc. acquired 6,000 shares by exercising or converting derivatives, had 4,243 shares withheld to cover taxes and gave 15 shares as a gift on Nov 2, 2026. Christopher R. Fenimore held 21,726 shares directly after the last reported transaction.
Key facts
- Insider
- Christopher R. Fenimore · EVP Finance CFO
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Nov 2, 2026 | M · exercise or conversion of a derivative | +6,000 | $381.92 | $2,291,520.00 | 25,984 | Direct |
| Nov 2, 2026 | F · tax withholding | −4,243 | $950.50 | $4,032,971.50 | 21,741 | Direct |
| Nov 2, 2026 | G · gift | −15 | $0.00 | $0.00 | 21,726 | Direct |
| Nov 2, 2026 | M · exercise or conversion of a derivativeNon-Qualified Stock Option (right to buy)Footnotes F2 | −6,000 | $0.00 | $0.00 | 0 | Direct |
Footnotes
- F1 These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
- F2 The stock option award vested in four equal annual installments, commencing one year after the date of grant.
More REGN filings
- 144
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 4
Filed Nov 4, 2026
- 144
Filed Nov 4, 2026
- 4
Filed Nov 3, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.